Bliss GVS Pharma bolsters board with two new independent directors

An update from Bliss Gvs Pharma Limited ( (IN:BLISSGVS) ) is now available.

Bliss GVS Pharma Limited has strengthened its board oversight by appointing Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah as additional non-executive independent directors for a five-year term starting April 3, 2026. The appointments, recommended by the Nomination and Remuneration Committee and approved via circular resolution, bring extensive finance, taxation, and governance experience to the board and will be placed before shareholders for approval through a postal ballot, underscoring the company’s focus on stronger corporate governance and regulatory compliance.

Mahadevan, a chartered accountant with over 35 years of multinational finance and turnaround experience, and Shah, a veteran tax and audit professional who sits on several listed company boards, are both independent of existing directors. Their inclusion is expected to enhance strategic financial oversight, risk management, and adherence to evolving SEBI governance norms, which may provide additional comfort to investors and other stakeholders regarding the company’s board strength and regulatory alignment.

More about Bliss Gvs Pharma Limited

Bliss GVS Pharma Limited operates in the pharmaceutical industry, focusing on the development, manufacturing, and sale of pharmaceutical products. The company serves domestic and international markets and is listed on both the National Stock Exchange of India and BSE, reflecting its presence in the Indian capital markets.

Average Trading Volume: 345,342

Technical Sentiment Signal: Buy

Current Market Cap: 24.79B INR

For a thorough assessment of BLISSGVS stock, go to TipRanks’ Stock Analysis page.